Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of N8-GP in Haemophilia A
NCT01480180Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2012
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
A Phase 3 trial of turoctocog alfa pegol in hemophilia A, sponsored by Novo Nordisk. Started Jan 2012; status: completed.
02
Drugs
turoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01480180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480180.